Aggressive B-Cell Non-Hodgkin Lymphoma

hematologic malignancy

Identifier: CI-CAN-00001751
Entity page: /cancer/aggressive-b-cell-non-hodgkin-lymphoma ↗
Edges: 651

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Aggressive B-Cell Non-Hodgkin Lymphoma altered in cohorts of …ALTERED_INderived15 of 143show all (up to 200)
← altered in cohorts of	SHCBP1 73 / 263 cases (28 %) · ssm · CGCI-BLGSP	—	—	Burkitt Lymphoma	1	Observed	gdc	graph →
← altered in cohorts of	VPS35 67 / 263 cases (25 %) · ssm · CGCI-BLGSP

Aggressive B-Cell Non-Hodgkin Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 108show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall molecule 84 trials (30 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	84	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 82 trials (22 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	82	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 45 trials (16 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	45	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 44 trials (13 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 44 trials (11 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 40 trials (19 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 39 trials (15 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 26 trials (11 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	26	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 23 trials (9 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall molecule 22 trials (7 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 16 trials (6 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 16 trials (9 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 16 trials (11 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 15 trials (3 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 13 trials (1 active) · roll-up of the cancer and its descendants	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	13	Observed	clinicaltrials	graph →

Aggressive B-Cell Non-Hodgkin Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 108show all (up to 200)

→ investigated in trials for

Cyclophosphamidesmall molecule

84 trials (30 active) · roll-up of the cancer and its descendants

—

Aggressive B-Cell Non-Hodgkin Lymphoma

Observed

Aggressive B-Cell Non-Hodgkin Lymphoma studied in …STUDIED_INderived10 of 400show all (up to 200)
→ studied in	NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Grade 3a Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Grade 3a Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active)	—	—	Grade 3a Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active)	—	—	Grade 3b Follicular Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Aggressive B-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 400 trials mapped (123 active)	—	—	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active)	—	—	Grade 3a Follicular Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains